

# Silicone gel sheet to improve cosmetic outcome of the scar after removal of an implantable central venous access device in childhood cancer survivors

<b>Submission date</b> 28/12/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/12/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 05/11/2008	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr H A Heij

### Contact details

Academic Medical Centre (AMC)  
Emma Children's Hospital and Vrije University Medical Centre  
Department of Pediatric Surgery (9d32)  
P.O. Box 22660  
Amsterdam  
Netherlands  
1100 DD  
+31 (0)20 566 5693  
[h.a.heij@amc.uva.nl](mailto:h.a.heij@amc.uva.nl)

## Additional identifiers

EudraCT/CTIS number

IRAS number

**ClinicalTrials.gov number**

**Secondary identifying numbers**

06/146; NTR815

## **Study information**

**Scientific Title**

**Acronym**

LiLa

**Study objectives**

1. Implantable central venous access device (ICVAD) removal, followed by six months of silicone gel sheet use, will result in a scar width within the normal range, and normal scar structure, and thus will be superior to two months of silicone gel sheets and no gel sheets.
2. A smaller and/or less hypertrophic scar will reduce the chance of being reminded to the stressful period during cancer treatment, resulting in a better body image and quality of life scores.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Received from the local medical ethics committee

**Study design**

Randomised, controlled, parallel group, multicentre trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Treatment

**Participant information sheet**

**Health condition(s) or problem(s) studied**

Hypertrophic scarring

**Interventions**

The application of a silicone gel sheet to optimise wound healing after removal of the ICVAD, and to reduce the size of the scar.

**Intervention Type**

Device

**Phase**

Not Specified

**Primary outcome measure**

Outcome variables regarding scar aspect:

1. Width in millimetres
2. Length in millimetres
3. Height (normal, 1 - 2 mm, 3 - 4 mm, 5 - 6 mm, more than 6 mm)
4. Vascularisaty (normal, pink, red, purple)
5. Pigmentation (normal, hypopigmentation, mixed pigmentation, hyperpigmentation)
6. Pliability (normal, supple, yielding, firm, adherent)
7. Pain (nine point scale)
8. Itching (nine point scale)

Children whose age is of twelve to eighteen years get standardised questionnaires on body image (minimum score eight, maximum score 40), and quality of life (functional and symptom status: 11 items with a range from one to four, global health status: two items with a range from one to seven).

**Secondary outcome measures**

No secondary outcome measures

**Overall study start date**

01/10/2006

**Completion date**

01/10/2008

**Eligibility****Key inclusion criteria**

1. Children who are in follow-up for cancer treatment, and have an ICVAD, which is planned to be removed, are eligible for the study
2. The children should be between one and eighteen years old

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

1 Years

**Upper age limit**

18 Years

**Sex**

Both

**Target number of participants**

36

**Key exclusion criteria**

Children are excluded for the study when they had an ICVAD on an other location than the chest wall, when the ICVAD was removed because of an infection, or when the child received radiotherapy on the chest. This latter criterion is because of the damage to the skin during radiotherapy.

**Date of first enrolment**

01/10/2006

**Date of final enrolment**

01/10/2008

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

**Academic Medical Centre (AMC)**

Amsterdam

Netherlands

1100 DD

**Sponsor information****Organisation**

Vrije University Medical Centre (VUMC) (The Netherlands)

**Sponsor details**

Van der Boechorststraat 7

Amsterdam

Netherlands

1081 BT

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.vumc.nl/>

**ROR**

<https://ror.org/00q6h8f30>

## **Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

Vrije University Medical Centre (VUMC) (The Netherlands)

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration